LENZ Therapeutics (LENZ) Other Non Operating Income (2021 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Other Non Operating Income of $3000.0 for Q1 2026, up 127.27% year-over-year from $1320.0 in Q1 2025, and up 100.72% quarter-over-quarter from -$417000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Other Non Operating Income (2021 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Other Non Operating Income for 6 consecutive years, with $3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 127.27% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at -$229000.0 (down 114.08% YoY), while the FY2025 annual figure was -$243000.0, down 184.08% from the prior year.
- Other Non Operating Income grew to $3000.0 in Q1 2026 per LENZ's latest filing, from -$417000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $2.2 million in Q4 2022 and bottomed at -$1.3 million in Q1 2024.
- Historically, Other Non Operating Income has averaged $278235.3 across 5 years, with a median of $3000.0 in 2026.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 21420.0% — and 2025, when it sank 5312.5%.
- LENZ Therapeutics' Other Non Operating Income stood at $2.2 million in 2022, then plunged by 87.59% to $267000.0 in 2023, then slumped by 97.0% to $8000.0 in 2024, then tumbled by 5312.5% to -$417000.0 in 2025, then soared by 100.72% to $3000.0 in 2026.
- Business Quant data shows LENZ's Other Non Operating Income at $3000.0 in Q1 2026, -$417000.0 in Q4 2025, and -$14000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | -417,000.00 |
| Sep 30, 2025 | -14,000.00 |
| Jun 30, 2025 | 199,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | -1.35 Mn |
| Dec 31, 2023 | 267,000.00 |
| Sep 30, 2023 | -101,000.00 |
| Jun 30, 2023 | -18,000.00 |
| Mar 31, 2023 | -54,000.00 |
| Dec 31, 2022 | 2.15 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 840,000.00 |
| Mar 31, 2022 | 123,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 10,000.00 |